• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

New Alzheimer’s Drug Slows Decline, But Its Trial Is Linked To Deaths

December 2, 2022 by Deborah Bloomfield

The experimental drug lecanemab has been shown to slow cognitive decline in people with early Alzheimer’s disease. While the long-awaited trial has been heralded as a “historic moment for dementia research”, the death of some participants in the research has sparked concerns about the risk for some people.

Lecanemab is a monoclonal antibody that works by actively removing sticky gunk, known as amyloid-beta, that builds up in the brains of people with Alzheimer’s. During an 18-month trial of almost 1,800 people with early Alzheimer’s, they found that the drug slowed cognitive and functional decline by 27 percent.

Advertisement

Biogen and Eisai, the makers of the drug, stoked some excitement about the trial in September, but the full data has now been published in a prestigious peer-reviewed journal. 

“This is the first time a drug has been shown to both reduce the disease in the brain and slow memory decline in clinical trials”, Dr Susan Kohlhaas, Director of Research at Alzheimer’s Research UK, said in a statement.

“Although the benefits were small and came with significant side effects, it marks the arrival of a treatment that can slow the course of Alzheimer’s disease. With all this excitement, there are still many questions and challenges we need to address”, continued Dr Kohlhaas.

Advertisement

The promising results have been somewhat marred by a number of deaths in trials and there are some worries about whether the drug is safe for some patients, especially those taking blood thinners.

At least two people in the trial died after taking the drug, according to media reports by STAT News and Science.  One of these fatalities was a 65-year-old woman who died from a massive brain hemorrhage that some researchers link to the drug. The other was a man in his late 80s who was taking a blood thinner for a heart condition. 

Paired with these two deaths, the data from the trial shows that six lecanemab-treated patients suffered from strokes. 

Advertisement

Biogen and Eisai deny that the trials show the drug is risky. They claim that neither of the deaths was directly related to treatment and the number of deaths in the placebo group and in the lecanemab-treated group was similar. 

Nevertheless, the potentially related deaths will raise some eyebrows and could impact decisions about how widely the drug should be prescribed if – and it’s still an if – it is eventually approved by regulators.

“Recent reports of two deaths from strokes, attributed to a side-effect of the drug, are concerning. The data published today indicate that six lecanemab-treated patients suffered strokes during the trial compared with two in the placebo group. Treatment, therefore, does carry risks, and in some rare cases this can be severe or life-threatening,” commented Rob Howard, Professor of Old Age Psychiatry at UCL, who was not involved in the research.

Advertisement

“I suspect that the lack of demonstrable clinical effectiveness will mean that lecanemab will not be taken up widely within healthcare systems around the World, although there will always be those whose heart rules their head”, added Professor Howard. 

The results of the clinical trial were published on November 29 in the New England Journal of Medicine.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Afghan journalists beaten in Taliban detention, editor says
  2. Syria sees spike in COVID-19 cases as fears grow of new wave
  3. U.S. Senate confirms deputy trade representative
  4. Improving startup results through female leadership

Source Link: New Alzheimer's Drug Slows Decline, But Its Trial Is Linked To Deaths

Filed Under: News

Primary Sidebar

  • If They Take Fluoride Out Of The Water, What Could Happen To Americans’ Teeth?
  • Paraglider Accidentally Flies Into The “Death Zone” 8,500 Meters Up – And Survives
  • World’s Oldest Fingerprint, Bioacoustics Could Give Us “A Peek Into The Language Of Wolves”, And Much More This Week
  • Please Stop Jamming Coins Into The Rocky Cracks Of Legendary Giant’s Causeway
  • We’re A Step Closer To Knowing Who Made The Earliest Known Stone Tools
  • These Little Birds Are All But Extinct – But There Is Still Time To Save Them
  • The Three Types Of Female Orgasm
  • Elon Musk Has Announced His Bombastic Plan To Get Humans To Mars
  • China Unveils World’s Largest Offshore Wind Turbine With Hub Height Of 185 Meters
  • Oldest Fingerprint, AI Decoding Wolf Language, And Injecting Life On Other Worlds?
  • “There Are Glimmers Of Hope”: Search For One Of The World’s Most Endangered Pigeons Just Scored A Big Win
  • Earth Has A 1-In-100,000 Chance Of Being Ejected From The Solar System Due To A Passing Star
  • “Necrobotics” Turns Dead Spider Corpses Into Biohybrid Robots
  • Why Even Traveling Close To The Speed Of Light Is So Hard
  • Peer Into The Universe’s Distant Past Thanks To JWST’s Longest-Exposure Photo Yet
  • First Evidence For Chubby Cheeks In Dinosaurs Challenges Our Understanding Of How They Chewed
  • The 2021 “Heat Dome” Killed Her Mother. Now, She’s Suing The Oil Companies Responsible
  • Two Of The Most Destructive Termites Got It On, Sparking Hybrid Threat In Florida
  • The Mad Gasser of Mattoon: A Story Of Anxiety And Hysteria In America’s Heartland
  • Tourists Swimming With Orcas In Mexico As Tour Guides Exploit Legal Loopholes
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version